Literature DB >> 12435703

Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins.

Andrea M Hujer1, Kristine M Hujer, Marion S Helfand, Vernon E Anderson, Robert A Bonomo.   

Abstract

Site saturation mutagenesis of the 238 position in the SHV beta-lactamase was performed to identify the complete sequence requirements needed for the extended spectrum beta-lactamase (ESBL) phenotype. MICs (in micrograms per milliliter) in an isogenic background, Escherichia coli DH10B, demonstrated that the Gly238Ala mutation conferred the most resistance to penicillins and cephalosporins. The absolute increase in resistance was greatest against cefotaxime for the Gly238Ala mutant (0.06 to 8 micro g/ml). Except for the strain possessing the Gly238Pro beta-lactamase, ceftazidime MICs were also elevated. None of the mutant SHV beta-lactamases were expressed in as great an amount as the wild-type beta-lactamase. Kinetic analysis of the Gly238Ala mutant revealed that penicillin and cephalosporin substrates have a lower K(m) for the enzyme because of this mutation. Ampicillin and piperacillin MICs were inversely proportional to the side chain volume of the amino acid in cases larger than Ser, suggesting that steric considerations may be a primary requirement for penicillin resistance. Secondary structural effects explain increased resistance to oxyiminocephalosporins. Based upon this study, we anticipate that additional mutations of Gly238 in the SHV beta-lactamase will continue to be discovered with an ESBL (ceftazidime or cefotaxime resistant) phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435703      PMCID: PMC132793          DOI: 10.1128/AAC.46.12.3971-3977.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  SHV-13, a novel extended-spectrum beta-lactamase, in Klebsiella pneumoniae isolates from patients in an intensive care unit in Amsterdam.

Authors:  M Yuan; L M Hall; P H Savelkoul; C M Vandenbroucke-Grauls; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Predicting the emergence of antibiotic resistance by directed evolution and structural analysis.

Authors:  M C Orencia; J S Yoon; J E Ness; W P Stemmer; R C Stevens
Journal:  Nat Struct Biol       Date:  2001-03

3.  Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae.

Authors:  D L Paterson; L B Rice; R A Bonomo
Journal:  Clin Microbiol Infect       Date:  2001-12       Impact factor: 8.067

4.  A standard numbering scheme for the class A beta-lactamases.

Authors:  R P Ambler; A F Coulson; J M Frère; J M Ghuysen; B Joris; M Forsman; R C Levesque; G Tiraby; S G Waley
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

5.  Probing the active site of beta-lactamase R-TEM1 by informational suppression.

Authors:  F Lenfant; R Labia; J M Masson
Journal:  Biochimie       Date:  1990 Jun-Jul       Impact factor: 4.079

6.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

7.  Interactions of new plasmid-mediated beta-lactamases with third-generation cephalosporins.

Authors:  R Labia; A Morand; K Tiwari; J Sirot; D Sirot; A Petit
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 8.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

9.  Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases.

Authors:  Andrea M Hujer; Malcolm G P Page; Marion S Helfand; Bethany Yeiser; Robert A Bonomo
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

10.  Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance.

Authors:  A M Hujer; K M Hujer; R A Bonomo
Journal:  Biochim Biophys Acta       Date:  2001-05-05
View more
  22 in total

1.  Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamases.

Authors:  Andrea M Hujer; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.

Authors:  Angela Novais; Rafael Cantón; Teresa M Coque; Andrés Moya; Fernando Baquero; Juan Carlos Galán
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

4.  High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognition.

Authors:  Pierre-Yves De Wals; Nicolas Doucet; Joelle N Pelletier
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

Review 5.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

6.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

7.  Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.

Authors:  Marisa L Winkler; Elizabeth A Rodkey; Magdalena A Taracila; Sarah M Drawz; Christopher R Bethel; Krisztina M Papp-Wallace; Kerri M Smith; Yan Xu; Jeffrey R Dwulit-Smith; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2013-02-04       Impact factor: 7.446

8.  Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Authors:  Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton; Marion J Skalweit
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Authors:  Sarah M Drawz; Christopher R Bethel; Kristine M Hujer; Kelly N Hurless; Anne M Distler; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

10.  Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Authors:  Sarah M Drawz; Maja Babic; Christopher R Bethel; Magda Taracila; Anne M Distler; Claudia Ori; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.